SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (17579)3/18/1998 9:15:00 AM
From: Arthur Radley  Read Replies (1) | Respond to of 32384
 
Someone needs to rush over to John O"Neils house this morning and hide his guns and hemlock(:>). Take him some Valium. 15 9/16.



To: Henry Niman who wrote (17579)3/18/1998 9:28:00 AM
From: Sleepman  Read Replies (4) | Respond to of 32384
 
Henry,
The news is now out about the leptin deal.
My humble analysis does not think it is all that great, but I am interested in others opinions. SmithKlein gets the compound for relatively little stock and royalties that were not outlined in the press release. LGND gets more dilution of shares and unclear milestone payments and royalties. Do you really think that this is a good deal? Dan


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News